These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29212974)

  • 1. [IgE-κ type multiple myeloma achieving complete response with novel agents].
    Takei T; Ishida T; Ikeda M; Shingaki S; Miyazaki K; Yoshiki Y; Abe Y; Okazuka K; Iki S; Tsukada N; Suzuki K
    Rinsho Ketsueki; 2017; 58(11):2232-2237. PubMed ID: 29212974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
    Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
    Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.
    van de Velde H; Londhe A; Ataman O; Johns HL; Hill S; Landers E; Berlin JA
    Eur J Haematol; 2017 Mar; 98(3):269-279. PubMed ID: 27859769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports.
    Le TX; Wolf JL; Peralta CA; Webber AB
    Am J Kidney Dis; 2017 Jun; 69(6):858-862. PubMed ID: 28320553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
    Dimopoulos MA; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Spencer A; Knop S; Bahlis NJ; Renner C; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel JF
    Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
    Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
    Takamatsu H; Munemoto S; Murata R; Terasaki Y; Nakajima K; Nakao S
    Anticancer Res; 2013 Dec; 33(12):5681-5. PubMed ID: 24324117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
    Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of newly diagnosed myeloma.
    Rajkumar SV; Palumbo A
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1141-56, ix-x. PubMed ID: 17996592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
    Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
    J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial treatment of transplant candidates with multiple myeloma.
    Moreau P; Touzeau C
    Semin Oncol; 2013 Oct; 40(5):585-91. PubMed ID: 24135403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
    Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
    Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Achievement of hemodialysis discontinuation with lenalidomide and dexamethasone therapy in a refractory BJP-type multiple myeloma patient].
    Uchida T; Inoue M; Hua J; Hagihara M
    Rinsho Ketsueki; 2016 May; 57(5):613-7. PubMed ID: 27263787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.
    Ahn SY; Jung SH; Joo YD; Lee WS; Lee SM; Choi CW; Kim SJ; Kim K; Lee JJ;
    Ann Hematol; 2014 Sep; 93(9):1571-7. PubMed ID: 24728664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction therapy in multiple myeloma.
    Harousseau JL
    Hematology Am Soc Hematol Educ Program; 2008; ():306-12. PubMed ID: 19074101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.